NCT00328952 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Farhall J, Gehrke M
Coping with hallucinations: exploring stress and coping framework. Br J Clin Psychol. 1997 May;36 ( Pt 2):259-61.
Haddock G, McCarron J, Tarrier N, Faragher EB
Scales to measure dimensions of hallucinations and delusions: the psychotic symptom rating scales (PSYRATS). Psychol Med. 1999 Jul;29(4):879-89.
Nayani TH, David AS
The auditory hallucination: a phenomenological survey. Psychol Med. 1996 Jan;26(1):177-89.
Shergill SS, Murray RM, McGuire PK
Auditory hallucinations: a review of psychological treatments. Schizophr Res. 1998 Aug 17;32(3):137-50. Review.

Naturalistic Multicenter Study of Changes in Auditory Verbal Hallucination During Atypical Antipsychotic Treatment of Schizophrenia

Clinical trial NCT00328952 - References